Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Rituximab

Catalog #:   DHC90705 Specific References (50) DATASHEET
Host species: Chimeric
Isotype: IgG1-kappa
Applications: Research Grade Biosimilar
Expression system: Mammalian Cells
Overview

Catalog No.

DHC90705

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Chimeric

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20

Concentration

4.3 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P11836

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

IDEC-C2B8, CAS: 174722-31-7

Clone ID

Rituximab

Data Image
  • SDS-PAGE
    SDS PAGE for Rituximab
  • SEC-HPLC
    The purity of this product is >95% as determined by SEC-HPLC.
References

Clinical and Electrodiagnostic Findings in Anti-myelin-Associated Glycoprotein Antibody Polyneuropathy: A Single Center Review., PMID:40513035

Long-Term Outcomes of Rituximab Therapy in Autoimmune Hemolytic Anemia: A Systematic Review and Meta-Analysis., PMID:40510077

Therapeutic Challenges and New Era in Fibrillary Glomerulonephritis with the Introduction of DNAJB9: Experience from a Tertiary Nephrology Center., PMID:40507471

A Triple Oral Combination of Bendamustine, Acalabrutinib, and Venetoclax Demonstrates Efficacy Against Mantle Cell Lymphoma In Vitro and In Vivo., PMID:40507368

Extravascular leakage of dexrazoxane that occurred in a patient with diffuse large B-cell lymphoma: a case report., PMID:40506789

Efficacy of rituximab versus cyclophosphamide in connective tissue disease‑related interstitial lung disease: a systematic review and meta-analysis., PMID:40506621

Emerging Role of Targeted Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders., PMID:40506618

Abatacept and multiple therapeutic bronchoscopies as salvage therapy for refractory tracheobronchial inflammation and stenosis in GPA., PMID:40506105

Effectiveness of anti-CD20 therapies following natalizumab discontinuation: insights from a cohort study., PMID:40505538

Relapse and beyond: Navigating the long-term clinical impacts of immune thrombotic thrombocytopenic purpura., PMID:40505364

FcRn inhibitors in immune thrombocytopenia: A comprehensive review of therapeutic advances and clinical outcomes., PMID:40505332

A single dose of a CD137 antibody-drug conjugate protects nonhuman primate allogeneic HCT recipients against acute GVHD., PMID:40504994

Synchronous MALT lymphoma and gastric adenocarcinoma., PMID:40503979

Diagnosis and treatment of metachronous multiple primary carcinoma: A case report and review of literature., PMID:40503404

Rituximab-based regimens for primary cardiac lymphoma: A systematic review of outcomes, challenges and future directions., PMID:40503399

Investigating outcomes and treatment of long coronavirus disease 2019 in patients with multiple sclerosis treated with rituximab: A case series study., PMID:40503046

Current Status of Pig-to-NHP Xenotransplantation Research in Korea., PMID:40500644

Clinical uptake of an antigen-based approach to membranous nephropathy: a survey of general nephrologists and glomerular disease experts., PMID:40500560

Combination therapy of rituximab and mycophenolate in patients with systemic sclerosis and primary cardiac involvement refractory to cyclophosphamide: a retrospective exploratory analysis of 10 cases., PMID:40499976

Mathematical modeling of Taylor-Aris dispersion-assisted mass spectrometry for the study of operating conditions., PMID:40499387

Copanlisib in combination with rituximab and bendamustine for transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma patients: Results from the phase II multicentre FIL Copa-BR trial from Fondazione Italiana Linfomi (FIL)., PMID:40495420

Mycosis Fungoides, Sézary Syndrome, and Cutaneous B-Cell Lymphomas: 2025 Update on Diagnosis, Risk-Stratification, and Management., PMID:40495407

Comparison and analysis of biological drug consumption in two Italian hospital settings: Governance actions and prescribing appropriateness., PMID:40494065

Prognosis of essential mixed cryoglobulinemia and connective tissue disease-related cryoglobulinemia after rituximab-induced remission., PMID:40493895

A 14-year girl with thrombotic thrombocytopenic purpura and Sjögren's syndrome., PMID:40492669

Factors for Rituximab Refractoriness in AQP4-IgG+ NMOSD: A Cohort Study., PMID:40492601

Economic Evaluation of Rituximab Versus Corticosteroid-Cyclophosphamide or Cyclosporine in Patients With Membranous Nephropathy in Republic of Korea., PMID:40492539

Rituximab as First-Line Compared to Escalation Immunotherapy Is Associated With Lower Disability Accumulation in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder: A Multicenter Cohort Study From Germany and the United Kingdom., PMID:40492480

CD20 targeted nanomedicine for GCB-diffuse large B-cell lymphoma through synergistic effects of apoptosis and ferroptosis., PMID:40492153

Dual BLyS/APRIL targeted therapy with telitacicept in rituximab-refractory SLE-associated neuromyelitis optica spectrum disorder: a case report., PMID:40491913

Therapeutic Choices in Systemic Sclerosis-Associated Interstitial Lung Disease, a Survey of 2 International Research Groups., PMID:40489954

Monitoring anti-Rituximab antibodies in myasthenia gravis affects the time to event during Rituximab treatment., PMID:40488894

Safety of glucocorticoid dose reduction in microscopic polyangiitis: a multicentre REVEAL cohort study., PMID:40488413

Nation-wide cohort study of Japanese patients with ANCA-associated vasculitis using rituximab: effectiveness and safety after two years., PMID:40488401

Extranodal Marginal Zone Lymphoma Presenting as Acute Kidney Injury due to Cast Nephropathy: A Case Report., PMID:40487070

Advances and challenges in leukemia treatment: A focus on monoclonal antibodies and emerging therapies., PMID:40486885

Dual Autoimmunity: A Case Report of the Sequential Development of Systemic Lupus Erythematosus in a Patient With Anti-MDA5 Dermatomyositis., PMID:40486387

Treatment of Nephrotic Syndrome With Antinephrin Antibodies Using Plasmapheresis, Rituximab, and Mycophenolate Mofetil., PMID:40485695

Persistent B Cell Depletion After Rituximab for Autoimmune and Glomerular Diseases: A Case Series., PMID:40485690

What Is the Evidence on Immunomodulators and Immunosuppressants for Progressive Multiple Sclerosis? - A Cochrane Review Summary with Commentary., PMID:40485316

How well does acalabrutinib work and how safe is it to treat patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have had previous treatments? a plain language summary of 2 key studies., PMID:40485230

[Diagnosis, treatment, and genetic analysis of five cases of primary atypical hemolytic uremic syndrome]., PMID:40484823

[Clinical characteristics and outcomes of elderly patients with stage Ⅰ diffuse large B-cell lymphoma: a study by the Jiangsu Cooperative Lymphoma Group (JCLG)]., PMID:40484818

Complex presentation of probable catastrophic antiphospholipid syndrome: diagnostic dilemmas and treatment strategies., PMID:40484440

Role of Chimeric Antigen Receptor-Expressing Cell Therapy in Immune-Mediated Kidney Diseases: A Review., PMID:40484342

Long-term maintenance of remission with spacing of rituximab infusions based on the individualised patient risk profile in ANCA-associated vasculitis: a pilot study., PMID:40480651

Haemophagocytic lymphohistiocytosis (HLH) secondary to measles in an adult with a loss of post-vaccination humoral immunity following rituximab., PMID:40480240

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)., PMID:40479620

The TMA team and TTP pathway improved outcomes in a cohort with Thrombotic thrombocytopenic purpura., PMID:40478853

The Use of Biologics for Thyroid Eye Disease., PMID:40478400

Datasheet

Document Download

Research Grade Rituximab.pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Rituximab [DHC90705]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only